A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

Conditions:   Carcinoma, Squamous Cell of Head and Neck;   Carcinoma, Non-Small-Cell Lung;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Non-small Cell Lung Cancer;   Human Papilloma Virus
Interventions:   Biological: ilixadencel;   Drug: Pembrolizumab
Sponsors:   Immunicum AB;   PPD
Not yet recruiting

https://ift.tt/2Pe8cz4